GlassScriptPhysician profile
Felix Urman
NPI 1902844210
$1,850.60
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2022: $1,290.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $990.00 | 2022 | |
| Teladoc Health, INC. | $300.00 | 2022 | |
| Abbvie INC. | $128.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $123.55 | 2019 | |
| Sun Pharmaceutical Industries INC. | $60.31 | 2019 | |
| Galderma Laboratories, L.P. | $55.73 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $55.44 | 2019 | |
| Lilly USA, LLC | $28.25 | 2019 | |
| Janssen Biotech, INC. | $27.87 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.11 | 2019 | |
| Genzyme Corporation | $14.60 | 2019 | |
| Biofrontera INC. | $13.65 | 2019 | |
| Pfizer INC. | $13.10 | 2019 | |
| Ucb, INC. | $12.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Urman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.